Published online Oct 26, 2021. doi: 10.4252/wjsc.v13.i10.1564
Peer-review started: July 6, 2021
First decision: July 29, 2021
Revised: August 2, 2021
Accepted: September 15, 2021
Article in press: September 15, 2021
Published online: October 26, 2021
Processing time: 111 Days and 20.4 Hours
The development of “mini-guts” organoid originates from the identification of Lgr5+ intestinal stem cells (ISCs) and circumambient signalings within their specific niche at the crypt bottom. These in vitro self-renewing “mini-guts”, also named enteroids or colonoids, undergo perpetual proliferation and regulated differentiation, which results in a high-performance, self-assembling and physiological organoid platform in diverse areas of intestinal research and therapy. The triumphant reconstitution of ISC niche in vitro also relies on Matrigel, a heterogeneous sarcoma extract. Despite the promising prospect of organoids research, their expanding applications are hampered by the canonical culture pattern, which reveals limitations such as inaccessible lumen, confine scale, batch to batch variation and low reproducibility. The tumor-origin of Matrigel also raises biosafety concerns in clinical treatment. However, the convergence of breakthroughs in cellular biology and bioengineering contribute to multiform reconstitution of the ISC niche. Herein, we review the recent advances in the microfabrication of intestinal organoids on hydrogel systems.
Core Tip: Organoid technique results in a high-performance, self-assembling and physiological platform in intestinal research and therapy. Despite the promising prospect of organoids research, their expanding applications are hampered by the canonical culture pattern, which reveals limitations such as inaccessible lumen, confine scale, batch to batch variation and low reproducibility. The tumor-origin of Matrigel also raises biosafety concerns in clinical treatment. The convergence of breakthroughs in cellular biology and bioengineering contribute to the development of biomaterial-based matrix or bioink for intestinal stem cells and incorporation of 3D printing and organ-on-a-chip technique, which may further advance organoid in future pathophysiological studies or functional tissue reconstitution.